A Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Volanesorsen (Primary) ; Volanesorsen (Primary) ; Moxifloxacin
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 07 Mar 2017 Status changed from recruiting to completed.
- 29 Sep 2016 New trial record